📊 IDXG Key Takeaways
Is Interpace Biosciences, Inc.. (IDXG) a Good Investment?
Interpace Biosciences maintains a fortress balance sheet with minimal leverage, strong liquidity, and robust free cash flow generation, but faces material headwinds with 17.5% YoY revenue decline that overshadows operational strength. The elevated net margin of 63.5% suggests potential one-time gains masking underlying business deterioration, warranting cautious observation of revenue stabilization before increased conviction.
Operating fundamentals are solid with strong gross/operating margins, positive free cash flow, and low leverage. However, a sharp revenue decline and net income far exceeding operating profit suggest non-recurring items and raise earnings quality concerns. Maintain a neutral stance until topline stabilizes and cash generation proves repeatable on a normalized basis.
Why Buy Interpace Biosciences, Inc.. Stock? IDXG Key Strengths
- Exceptionally strong balance sheet with 0.08x debt-to-equity ratio and $2.5M cash
- Superior liquidity metrics (1.94x current ratio, 1.72x quick ratio) provide operational flexibility
- Positive free cash flow generation of $5.5M with 14.1% FCF margin despite revenue pressure
- Excellent interest coverage ratio of 26.2x indicating zero near-term solvency risk
- EPS growth of 122.5% YoY demonstrates improving per-share economics through capital management
- Healthy gross and operating margins
- Positive free cash flow with double-digit FCF margin
- Low leverage and strong interest coverage
IDXG Stock Risks: Interpace Biosciences, Inc.. Investment Risks
- Sharp 17.5% YoY revenue decline indicates loss of market share or structural headwinds in diagnostic/surgical instruments sector
- Unusually high net margin of 63.5% suggests presence of one-time gains or non-recurring items masking operational reality
- Flat net income YoY combined with revenue decline raises questions about underlying business quality and sustainability
- Limited insider activity (2 Form 4 filings in 90 days) provides minimal signals on management confidence
- Medical device/diagnostic sector exposure to reimbursement pressure and competitive dynamics
- Revenue contraction signals potential demand or reimbursement pressure
- Earnings quality risk: net income far above operating profit suggests one-time items
- Modest cash balance relative to scale heightens liquidity sensitivity
Key Metrics to Watch
- Sequential revenue trends and year-over-year growth trajectory to confirm stabilization
- Gross margin sustainability as revenue base contracts
- Operating cash flow consistency relative to net income
- Operating margin expansion or compression in future periods
- Revenue growth (YoY)
- Operating cash flow vs operating income (FCF conversion and below-the-line impacts)
Interpace Biosciences, Inc.. (IDXG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Interpace Biosciences, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IDXG Profit Margin, ROE & Profitability Analysis
IDXG vs Healthcare Sector: How Interpace Biosciences, Inc.. Compares
How Interpace Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Interpace Biosciences, Inc.. Stock Overvalued? IDXG Valuation Analysis 2026
Based on fundamental analysis, Interpace Biosciences, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Interpace Biosciences, Inc.. Balance Sheet: IDXG Debt, Cash & Liquidity
IDXG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Interpace Biosciences, Inc..'s revenue has grown significantly by 14% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.40 reflects profitable operations.
IDXG Revenue Growth, EPS Growth & YoY Performance
IDXG Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.8M | -$640.0K | $0.03 |
| Q2 2025 | $9.2M | -$640.0K | $0.04 |
| Q1 2025 | $10.2M | $708.0K | $0.06 |
| Q3 2024 | $9.1M | -$88.0K | $-0.02 |
| Q2 2024 | $11.0M | $175.0K | $0.04 |
| Q1 2024 | $9.8M | $351.0K | $0.08 |
| Q3 2023 | $8.2M | -$88.0K | $-0.02 |
| Q2 2023 | $7.4M | $175.0K | $0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Interpace Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
IDXG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Interpace Biosciences, Inc.. (CIK: 0001054102)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IDXG
What is the AI rating for IDXG?
Interpace Biosciences, Inc.. (IDXG) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 65% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IDXG's key strengths?
Claude: Exceptionally strong balance sheet with 0.08x debt-to-equity ratio and $2.5M cash. Superior liquidity metrics (1.94x current ratio, 1.72x quick ratio) provide operational flexibility. ChatGPT: Healthy gross and operating margins. Positive free cash flow with double-digit FCF margin.
What are the risks of investing in IDXG?
Claude: Sharp 17.5% YoY revenue decline indicates loss of market share or structural headwinds in diagnostic/surgical instruments sector. Unusually high net margin of 63.5% suggests presence of one-time gains or non-recurring items masking operational reality. ChatGPT: Revenue contraction signals potential demand or reimbursement pressure. Earnings quality risk: net income far above operating profit suggests one-time items.
What is IDXG's revenue and growth?
Interpace Biosciences, Inc.. reported revenue of $38.7M.
Does IDXG pay dividends?
Interpace Biosciences, Inc.. does not currently pay dividends.
Where can I find IDXG SEC filings?
Official SEC filings for Interpace Biosciences, Inc.. (CIK: 0001054102) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IDXG's EPS?
Interpace Biosciences, Inc.. has a diluted EPS of $0.89.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IDXG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Interpace Biosciences, Inc.. has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IDXG stock overvalued or undervalued?
Valuation metrics for IDXG: ROE of 109.9% (sector avg: 15%), net margin of 63.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy IDXG stock in 2026?
Our dual AI analysis gives Interpace Biosciences, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is IDXG's free cash flow?
Interpace Biosciences, Inc..'s operating cash flow is $5.8M, with capital expenditures of $356.0K. FCF margin is 14.1%.
How does IDXG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 63.5% (avg: 12%), ROE 109.9% (avg: 15%), current ratio 1.94 (avg: 2).
Why is IDXG's return on equity (ROE) so high?
Interpace Biosciences, Inc.. has a return on equity of 109.9%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 63.5% net margin.